Haemophilia B

1
Pipeline Programs
3
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
4 programs
1
Nonacog beta pegolPhase 31 trial
Nonacog beta pegolN/A1 trial
Nonacog beta pegolN/A1 trial
Refixia®N/A1 trial
Active Trials
NCT03690336Enrolling By Invitation10Est. Oct 2027
NCT03745924Enrolling By Invitation60Est. Dec 2027
NCT03875547Enrolling By Invitation20Est. Dec 2025
+1 more trials
Swedish Orphan Biovitrum
1 program
AlprolixN/A1 trial
Active Trials
NCT03655340CompletedEst. Mar 2022
CSL Behring
CSL BehringIL - Bradley
1 program
Observatory of Patients With Haemophilia B Treated by IdElvion®N/A1 trial
Active Trials
NCT05086575Active Not Recruiting222Est. Dec 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Novo NordiskNonacog beta pegol
CSL BehringObservatory of Patients With Haemophilia B Treated by IdElvion®
Novo NordiskRefixia®
Novo NordiskNonacog beta pegol
Novo NordiskNonacog beta pegol
Swedish Orphan BiovitrumAlprolix

Clinical Trials (6)

Total enrollment: 342 patients across 6 trials

NCT05365217Novo NordiskNonacog beta pegol

A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia B

Start: May 2022Est. completion: May 202430 patients
Phase 3Completed
NCT05086575CSL BehringObservatory of Patients With Haemophilia B Treated by IdElvion®

Observatory of Patients With Haemophilia B Treated by IdElvion®

Start: Dec 2021Est. completion: Dec 2027222 patients
N/AActive Not Recruiting
NCT03875547Novo NordiskRefixia®

Post-marketing Surveillance (Use Result Surveillance) With Refixia®

Start: Aug 2019Est. completion: Dec 202520 patients
N/AEnrolling By Invitation
NCT03745924Novo NordiskNonacog beta pegol

A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN

Start: Apr 2019Est. completion: Dec 202760 patients
N/AEnrolling By Invitation
NCT03690336Novo NordiskNonacog beta pegol

Adverse Event Data Collection From External Registries on Nonacog Beta Pegol

Start: Oct 2018Est. completion: Oct 202710 patients
N/AEnrolling By Invitation
NCT03655340Swedish Orphan BiovitrumAlprolix

A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France

Start: Sep 2018Est. completion: Mar 2022
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space